Vecuronium

Summary

Vecuronium (CHEMBL1201219) is an approved small-molecule nicotinic antagonist (ATC M03AC03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03AC03
• Clinical trials: 15
• Chemistry: 557.8 Da · C34H57N2O4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201219
Name	Vecuronium
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	39765
ChEBI	CHEBI:9939
ATC	M03AC03
Molecular formula	C34H57N2O4+
Molecular weight	557.8
InChIKey	BGSZAXLLHYERSY-XQIGCQGXSA-N

SMILES: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C

IUPAC name: [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

ChEBI definition: A 5α-androstane compound having 3α-acetoxy-, 17β-acetoxy-, 2β-piperidino- and 16β-N-methylpiperidinium substituents.

Pharmacological roles (ChEBI): nicotinic antagonist, neuromuscular agent, muscle relaxant, drug allergen.

Also known as: Vecuronium, Vecuronium cation, Vecuronium ion, SID50112721, vecuronium, VECURONIUM, VECURONIUM BROMIDE

Parent form; salt/anhydrous children: CHEMBL1200629

Patent coverage: 13 distinct patent families (26 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Voltage-gated inwardly rectifying potassium channel KCNH2, Histamine H3 receptor, Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE4	9
PHASE3	2
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01690338	PHASE4	UNKNOWN	A Study of Residual Curarization Incidence in China
NCT02123355	PHASE4	UNKNOWN	The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery
NCT02134093	PHASE4	UNKNOWN	Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients
NCT02237443	PHASE4	COMPLETED	Mask Ventilation Before and After Neuromuscular Blockade
NCT02327923	PHASE4	COMPLETED	Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy
NCT03219294	PHASE4	COMPLETED	Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?
NCT03346057	PHASE4	COMPLETED	Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
NCT03371953	PHASE4	UNKNOWN	Evaluation of Atracurium-vecuronium Combination in Laparosocpic Surgery
NCT03540030	PHASE4	COMPLETED	Opioid-Free Shoulder Arthroplasty
NCT00473694	PHASE3	COMPLETED	Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
NCT00970762	PHASE3	COMPLETED	Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)
NCT07595393	PHASE2	NOT_YET_RECRUITING	A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade
NCT00552617	PHASE2	COMPLETED	A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
NCT07557576	Not specified	RECRUITING	Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing Cleft Surgery
NCT02619578	Not specified	COMPLETED	The Effect of TEAS on the Quality of Early Recovery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).